Publications by authors named "Susan L Ford"

Claim this Profile
S
Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.
Ronald D'Amico, Kelong Han, Sherene Min, Rebecca DeMoor, Marty St Clair, Susan L Ford

AIDS· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084.
Mark A Marzinke, Brett Hanscom, Daniel Haines, Kimberly K Scarsi, Yaw Agyei, Susan L Ford

J Int AIDS Soc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir pharmacokinetics in Asians with and without HIV.
Kelong Han, Ahmed A Abulfathi, Rashmi S Mehta, Romina A Nand, Mark A Marzinke, Susan L Ford

Int J Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.
Susan L Ford, Franco Felizarta, Kelong Han, Kehui Wang, Herta Crauwels

Clin Infect Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long-Acting Intramuscular Injections.
Kelong Han, Ronald D D'Amico, William R Spreen, Susan L Ford

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.
Sinead Delany-Moretlwe, Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Susan L Ford

J Int AIDS Soc· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.
Kelong Han, Ronald D D'Amico, William R Spreen, Susan L Ford

Antimicrob Agents Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
Mark A Marzinke, Kelong Han, Brett Hanscom, Xu Guo, Estelle Piwowar-Manning, Susan L Ford

Antimicrob Agents Chemother· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
Emilie R Elliot, Joseph W Polli, Parul Patel, Louise Garside, Richard Grove, Susan L Ford

J Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Kelong Han, Parul Patel, Scott McCallister, Alex R Rinehart, Yash Gandhi, Susan L Ford

Antimicrob Agents Chemother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Susan L Ford

Lancet HIV· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Shinichi Oka, Vicki Holohan, Takuma Shirasaka, Jun Yong Choi, Yeon-Sook Kim, Susan L Ford

HIV Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the (lateral thigh) muscles of healthy adult participants.
Kelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, Herta Crauwels, Claudia Leemereise, Susan L Ford

Antimicrob Agents Chemother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Parul Patel, Paula Teichner, Emilie Elliot, Marta Boffito, Milena Murray, Susan L Ford

Ther Adv Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel, Susan L Ford

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Parul Patel, Susan L Ford, Mark Baker, Claudia Meyer, Louise Garside

HIV Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Susan L Ford

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Mark A Marzinke, Jessica M Fogel, Zhe Wang, Estelle Piwowar-Manning, Ryan Kofron, Susan L Ford

Antimicrob Agents Chemother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Susan L Ford

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Susan L Ford

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
Jafar Sadik Shaik, Ethel D Weld, Stacey Edick, Edward Fuchs, Sharon Riddler, Susan L Ford

Br J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
Susan Swindells, Thomas Lutz, Lelanie Van Zyl, Norma Porteiro, Matthias Stoll, Susan L Ford

AIDS· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Hans Jaeger, Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Jaime Federico Andrade-Villanueva, Susan L Ford

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, Susan L Ford

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Susan L Ford

Lancet HIV· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis